LXEO Stock Analysis: Buy, Sell, or Hold?
LXEO - Lexeo Therapeutics, Inc. Common Stock
$5.50
-0.26 (-4.51%)
▼
5d:
-5.5%
30d:
-19.12%
90d:
-16.29%
HOLD
MODERATE Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 11, 2026
0d
Get Alerted When LXEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: LXEO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: LXEO shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: LXEO is currently trading at $5.50, which is considered oversold relative to its 30-day fair value range of $5.71 to $6.47.
Technical Outlook: Technically, LXEO is in a strong downtrend. The price is currently testing key support at $5.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: LXEO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.64 (+240.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, LXEO is in a strong downtrend. The price is currently testing key support at $5.45. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: LXEO has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $19.64 (+240.9%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$5.71 -
$6.47
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 240.9% below Wall St target ($19.64)
- CAUTION: 5-day price weakness (-5.5%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$5.71 -
$6.47
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$5.45
Resistance Level
$6.43
Current Trend
Strong Downtrend
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-4.06
Wall Street Target
$19.64
(+240.9%)
Share & Embed Analysis
Last updated: May 14, 2026 4:34 PM ET
Data refreshes hourly during market hours. Next update: 5:34 PM
Data refreshes hourly during market hours. Next update: 5:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is LXEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
6
Sells
Net
INSIDERS SELLING
Recent Transactions
Richard Nolan Townsend
SELL
55000 shares
2026-04-06
Jose Manuel Otero
SELL
3016 shares
2026-02-18
Richard Nolan Townsend
SELL
10173 shares
2026-02-18
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1036 | 58 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$73 | 58 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
19 analysts |
$208 | 49 HOLD |
|
RCKT
Rocket Pharmaceuticals I… |
STRONG BUY
18 analysts |
$9 | 55 HOLD |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$297 | 59 HOLD |
